GEG-tech’s agreement with tebu-bio expands the distribution of advanced vectorisation systems & tools, designed by GEG-tech (genetic engineering lab) into the European Market.
GEG-tech, the technology leader in advanced lentiviral vectorisation systems, announces a distribution agreement with tebu-bio to bolster its coverage of the European Market.
tebu-bio, is a pan-european distributor of speciality real agents for the life science industry. tebu-bio also runs a large variety of in-vitro assays. The firm has established long standing relationships with its suppliers and clients and offers a first rate service and is considered as a reliable source for real-agents critical to customers’ research and product development.
GEG-tech has developed a unique know-how in advanced lentiviral vectorisation systems in a variety of R&D contexts, including, CAR-T Cells including CRISPRs. GEG-tech provides on-the-shelf and on-design vector systems as well as products & services leveraging its know-how: cell lines, animal models, bio-production optimisation, testing tools…
“We are glad to extend tebu-bio’s portfolio of offers with the distribution agreement of GEG-Tech’s technologies. The Agreement confirms tebu-bio’s positioning at the cutting-edge of innovation.” said Donald van Dyjk, tebu-bio’s General Manager.
“The tebu-bio Team is highly experienced in innovative reagents and has a powerful distribution network with premium clients across Europe. This agreement will contribute to make GEG-tech’s advanced vectorisation systems accessible, therefore helping customers succeed in their R&D challenges” said Antoine Duboscq, GEG-Tech’s CEO.